Results 101 to 110 of about 2,555,654 (307)

ANGPT1-based targeted drug screening: Identification of Tasosartan and its activity against tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Journal of International Medical Research
Objective Chronic myeloid leukemia treatment is hampered by resistance to tyrosine kinase inhibitors, which is driven in part by the activation of JAK/STAT signaling mediated by intracellular angiopoietin-1 (ANGPT1).
Min Zhang, Ping Wang, Yunsheng Ran, Ruiyin Li, Junzhao Wan, Jianta Wang, Dan Ma, Ping Liu   +7 more
doaj   +1 more source

Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure

American Journal of Hematology, EarlyView.
ABSTRACT BCOR and BCORL1 (BCOR/L1) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher
Atsushi Marumo, Arda Durmaz, Christopher Haddad, Aashray Mandala, Felipe de Almeida Sartori, Akram Abushamma, Serhan Unlu, Xiaorong Gu, Zachary Brady, Matteo D'Addona, Kartik Lakhotiya, Luca Guarnera, Masanori Yoshida, Monika M. Toma, Mark D. Orland, Carlos Bravo‐Perez, Carmelo Gurnari, Koichi Takahashi, Tomasz Skorski, Stephan Hutter, Torsten Haferlach, Marcin Wlodarski, Valeria Visconte, Jaroslaw P. Maciejewski   +23 more
wiley   +1 more source

New Bcr-Abl-independent mechanisms of resistance to imatinib treatment in chronic myelogenous leukaemia patients [PDF]

, 2008
Although rare in chronic phase myeloid leukemia (CML), primary or acquired resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in the advanced phases of disease.
Esposito, Nicola
core   +1 more source

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report

SAGE Open Medical Case Reports
Venetoclax, a BCL-2 inhibitor used in chronic lymphocytic leukemia and acute myeloid leukemia, has been rarely associated with autoimmune hemolytic anemia, mostly in chronic lymphocytic leukemia.
Karima Benallaoua, Pierre Lacoeuilhe, Benoît Gendrot, Sahra Muhammad, Guillemette Fouquet   +4 more
doaj   +1 more source

Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years.
Ole Haubjerg Nielsen, Ulrik Kristoffer Stoltze, Pernille Axél Gregersen, Marianne Hoffmann, Morten Lyng Høgild, Mette Klarskov Andersen, Lise Barlebo Ahlborn, Lisa Lyngsie Hjalgrim, Karin A. W. Wadt   +8 more
wiley   +1 more source

PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India

Tumor Biology, 2017
Platelet-derived growth factor receptor has been implicated in many malignant and non-malignant diseases. Platelet-derived growth factor receptor-α is a tyrosine kinase and a side target for imatinib, a revolutionary drug for the treatment of chronic ...
Sameer Ahmad Guru, Rashid Mir, Musadiq Bhat, Imtiyaz Najar, Mariyam Zuberi, Mamta Sumi, Mirza Masroor, Naresh Gupta, Alpana Saxena   +8 more
doaj   +1 more source

Nasal Tuft Cell Markers Are Predictive of Overall Survival in Sinonasal Neuroendocrine and Sinonasal Undifferentiated Carcinomas

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC) are rare aggressive malignancies with no established prognostic markers. Because features of POU2F3+ small cell lung carcinomas have been identified in both tumors, we evaluated immunostaining for POU2F3, a tuft cell transcription factor, and ...
Nikolina Dioufa, Ricardo V. Bruneto, Jennifer E. Douglas, Nithin D. Adappa, James N. Palmer, Noam A. Cohen, Michael A. Kohanski   +6 more
wiley   +1 more source

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

Haematologica, 2010
Background Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia.
Stéphane Flamant, William Ritchie, Joëlle Guilhot, Jeff Holst, Marie-Laure Bonnet, Jean-Claude Chomel, François Guilhot, Ali G. Turhan, John E.J. Rasko   +8 more
doaj   +1 more source

Translational Macrophage Mechano‐Immunotherapy for Next‐Generation Implantable Biomaterials

Advanced NanoBiomed Research, EarlyView.
This review explores how macrophage mechanosensing drives inflammation, fibrosis and foreign body responses to implanted biomaterials. It examines emerging pharmacological strategies to modulate mechanotransduction, alongside biomaterial platforms for localised drug delivery, clinical translation, regulatory considerations and standardised testing ...
Xueying Xu, Ian L. Chin, Richard P. Tan
wiley   +1 more source

Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways

Tumor Biology, 2017
Signal transducer and activator of transcription 5 and Akt pathways, implicated in signaling transduction downstream of BCR–ABL, play critical roles in the pathogenesis of chronic myeloid leukemia.
Majid Safa, Leila Jafari, Fatemeh Alikarami, Rima Manafi Shabestari, Ahmad Kazemi   +4 more
doaj   +1 more source